Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin

Experimental Cell Research

Volumn 319, Issue 20, 2013, Pages 3140-3149

  Liu, Yu ^a   Du, Feiya ^a   Chen, Wei ^a   Yao, Minya ^a   Lv, Kezhen ^a   Fu, Peifen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Breast cancer; Chemoresistance; Doxorubicin; DUSP4; EMT

Indexed keywords

BETA CATENIN; DOXORUBICIN; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL ASSAY; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MESENCHYME CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 84887146919     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.08.023     Document Type: Article

References (47)

1. Parkin D.M., Bray F., Ferlay J., Pisani P., et al. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., Wood W.C., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 2003, 21:588-592.
3. Drasin D.J., Robin T.P., Ford H.L., et al. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 2011, 13:226.
4. Li Q.Q., Xu J.D., Wang W.J., Cao X.X., Chen Q., Tang F., Chen Z.Q., Liu X.P., Xu Z.D., et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 2009, 15:2657-2665.
5. Christiansen J.J., Rajasekaran A.K., et al. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006, 66:8319-8326.
6. Hoshino H., Miyoshi N., Nagai K., Tomimaru Y., Nagano H., Sekimoto M., Doki Y., Mori M., Ishii H., et al. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem. Biophys. Res. Commun. 2009, 390:1061-1065.
7. Klymkowsky M.W., Savagner P., et al. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am. J. Pathol. 2009, 174:1588-1593.
8. Kurrey N.K., lgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., Bapat S.A., et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068.
9. Kalluri R., Weinberg R.A., et al. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
10. Thiery J.P., et al. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 2003, 15:740-746.
11. Mamuya F.A., Duncan M.K., et al. aV integrins and TGF-β-induced EMT: a circle of regulation. J. Cell. Mol. Med. 2012, 16:445-455.
12. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
13. Antoon J.W., Lai R., Struckhoff A.P., Nitschke A.M., Elliott S., Martin E.C., Rhodes L.V., Yoon N.S., Salvo V.A., Shan B., Beckman B.S., Nephew K.P., Burow M.E., et al. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci. Rep. 2012, 2:539.
14. Tian W., Chen J., He H., Deng Y., et al. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin. Transl. Oncol. 2012, (Aug 23. [Epub ahead of print]).
15. Black E.J., Walker M., Clark W., MacLaren A., Gillespie D.A., et al. Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogenesis 2002, 21:6540-6548.
16. Camps M., Nichols A., Arkinstall S., et al. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000, 14:6-16.
17. Chang L., Karin M., et al. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
18. Armes J.E., Hammet F., de Silva M., Ciciulla J., Ramus S.J., Soo W.K., Mahoney A., Yarovaya N., Henderson M.A., Gish K., Hutchins A.M., Price G.R., Venter D.J., et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogenesis 2004, 23:5697-5702.
19. Balko J.M., Cook R.S., Vaught D.B., Kuba M.G., Miller T.W., Bhola N.E., Sanders M.E., Granja-Ingram N.M., Smith J.J., Meszoely I.M., Salter J., Dowsett M., Stemke-Hale K., González-Angulo A.M., Mills G.B., Pinto J.A., Gómez H.L., Arteaga C.L., et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 2012, 18:1052-1059.
20. Britson J.S., Barton F., Balko J.M., Black E.P., et al. Deregulation of DUSP activity in EGFR-mutant lung cancer cell lines contributes to sustained ERK1/2 signaling. Biochem. Biophys. Res. Commun. 2009, 390:849-854.
21. Chitale D., Gong Y., Taylor B.S., Broderick S., Brennan C., Somwar R., Golas B., Wang L., Motoi N., Szoke J., Reinersman J.M., Major J., Sander C., Seshan V.E., Zakowski M.F., Rusch V., Pao W., Gerald W., Ladanyi M., et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogenesis 2009, 28:2773-2783.
22. Rottenberg S., Jonkers J., et al. MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. Breast Cancer Res. 2012, 14:324.
23. Waha A., Felsberg J., Hartmann W., von dem Knesebeck A., Mikeska T., Joos S., Wolter M., Koch A., Yan P.S., Endl E., Wiestler O.D., Reifenberger G., Pietsch T., Waha A., et al. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 2010, 70:1689-1699.
24. Han R., Xiong J., Xiao R., Altaf E., Wang J., Liu Y., Xu H., Ding Q., Zhang Q., et al. Activation of β-catenin signaling is critical for doxorubicin-induced epithelial-mesenchymal transition in BGC-823 gastric cancer cell line. Tumour Biol. 2013, 34:277-284.
25. Hu Q.D., Chen W., Yan T.L., Ma T., Chen C.L., Liang C., Zhang Q., Xia X.F., Liu H., Zhi X., Zheng X.X., Bai X.L., Yu X.Z., Liang T.B. TB, et al., NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 2012, 325:207-213.
26. Keyse S.M., et al. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008, 27:253-261.
27. Gaedcke J., Grade M., Jung K., Camps J., Jo P., Emons G., Gehoff A., Sax U., Schirmer M., Becker H., Beissbarth T., Ried T., Ghadimi B.M., et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosom. Cancer 2010, 49:1024-1034.
28. Gröschl B., Bettstetter M., Giedl C., Woenckhaus M., Edmonston T., Hofstädter F., Dietmaier F.W., et al. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int. J. Cancer 2013, 132:1537-1546.
29. Yip-Schneider M.T., Lin A., Marshall M.S., et al. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem. Biophys. Res. Commun. 2001, 280:992-997.
30. Teutschbein J., Haydn J.M., Samans B., Krause M., Eilers M., Schartl M., Meierjohann S., et al. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer 2010, 10:386.
31. Sieben N.L., Oosting J., Flanagan A.M., Prat J., Roemen G.M., Kolkman-Uljee S.M., van Eijk R., Cornelisse C.J., Fleuren G.J., van Engeland M., et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J. Clin. Oncol. 2005, 23:7257-7264.
32. Lawan A., Al-Harthi S., Cadalbert L., McCluskey A.G., Shweash M., Grassia G., Grant A., Boyd M., Currie S., Plevin R R., et al. Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J. Biol. Chem. 2011, 286:12933-12943.
33. Wang H.Y., Cheng Z., Malbon C.C., et al. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003, 191:229-237.
34. Hasegawa T., Enomoto A., Kato T., Kawai K., Miyamoto R., Jijiwa M., Ichihara M., Ishida M., Asai N., Murakumo Y., Ohara K., Niwa Y., Goto H., Takahashi M., et al. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogenesis 2008, 27:5684-5695.
35. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., Tan B.R., Krishnamurthi S.S., Burris H.A., Poplin E.A., Hidalgo M., Baselga J., Clark E.A., Mauro D.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25:3230-3237.
36. Ansieau S., Bastid J., Doreau A., Morel A.P., Bouchet B.P., Thomas C., Fauvet F., Puisieux I., Doglioni C., Piccinin S., Maestro R., Voeltzel T., Selmi A., Valsesia-Wittmann S., Caron de Fromentel C., Puisieux A., et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89.
37. Li J., Zhou B.P., et al. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11:49.
38. Lander R., Nordin K., LaBonne C., et al. The F-box protein Ppa is a common regulator of core EMT factors Twist, Snail, Slug, and Sip1. J. Cell Biol. 2011, 194:17-25.
39. Eckert L.B., Repasky G.A., Ulkü A.S., McFall A., Zhou H., Sartor C.I., Der C.J., et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 2004, 64:4585-4592.
40. Jancík S., Drábek J., Radzioch D., Hajdúch M., et al. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol. 2010, 2010:150960.
41. Kim R.K., Suh Y., Lim E.J., Yoo K.C., Lee G.H., Cui Y.H., Son A., Hwang E., Uddin N., Yi J.M., Kang S.G., Lee S.J., et al. A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer. Cancer Lett. 2013, 337:49-57.
42. Zhang Q., Bai X., Chen W., Ma T., Hu Q., Liang C., Xie S., Chen C., Hu L., Xu S., Liang T., et al. Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. Carcinogenesis 2013, 34:962-973.
43. Salnikov A.V., Liu L., Platen M., Gladkich J., Salnikova O., Ryschich E., Mattern J., Moldenhauer G., Werner J., Schemmer P., Büchler M.W., Herr I., et al. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One 2012, 7:e46391.
44. Han M., Wang Y., Liu M., Bi X., Bao J., Zeng N., Zhu Z., Mo Z., Wu C., Chen X., et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012, 103:1058-1064.
45. Cho K., Shin H.W., Kim Y.I., Cho C.H., Chun Y.S., Kim T.Y., Park J.W., et al. Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function. Free Radical Biol. Med. 2013, 60:201-210.
46. Sakulterdkiat T., Srisomsap C., Udomsangpetch R., Svasti J., Lirdprapamongkol K., et al. Curcumin resistance induced by hypoxia in HepG2 cells is mediated by multidrug-resistance-associated proteins. Anticancer Res. 2012, 32:5337-5342.
47. He C., Sun X.P., Qiao H., Jiang X., Wang D., Jin X., Dong X., Wang J., Jiang H., Sun X., et al. Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci. 2012, 103:528-534.